Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4511 | 14639-25-9 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral venous thrombosis | 139.22 | 47.23 | 24 | 1029 | 2304 | 90625090 |
| Thalamic infarction | 94.79 | 47.23 | 14 | 1039 | 498 | 90626896 |
| Obstructive defaecation | 70.72 | 47.23 | 10 | 1043 | 260 | 90627134 |
| Stoma site dermatitis | 70.15 | 47.23 | 10 | 1043 | 276 | 90627118 |
| Gastrointestinal stoma output abnormal | 66.31 | 47.23 | 10 | 1043 | 410 | 90626984 |
| Stoma site inflammation | 60.20 | 47.23 | 10 | 1043 | 764 | 90626630 |
| Underweight | 54.35 | 47.23 | 10 | 1043 | 1380 | 90626014 |
| Stoma site pain | 54.16 | 47.23 | 10 | 1043 | 1407 | 90625987 |
| Slow response to stimuli | 50.10 | 47.23 | 9 | 1044 | 1087 | 90626307 |
| Gastrointestinal stoma complication | 48.82 | 47.23 | 10 | 1043 | 2409 | 90624985 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral venous thrombosis | 133.68 | 42.86 | 24 | 1130 | 3238 | 110584907 |
| Thalamic infarction | 82.70 | 42.86 | 14 | 1140 | 1338 | 110586807 |
| Obstructive defaecation | 72.09 | 42.86 | 10 | 1144 | 252 | 110587893 |
| Stoma site dermatitis | 70.77 | 42.86 | 10 | 1144 | 289 | 110587856 |
| Gastrointestinal stoma output abnormal | 67.09 | 42.86 | 10 | 1144 | 422 | 110587723 |
| Stoma site inflammation | 58.36 | 42.86 | 10 | 1144 | 1025 | 110587120 |
| Underweight | 54.46 | 42.86 | 10 | 1144 | 1520 | 110586625 |
| Stoma site pain | 51.97 | 42.86 | 10 | 1144 | 1953 | 110586192 |
| Gastrointestinal stoma complication | 46.82 | 42.86 | 10 | 1144 | 3279 | 110584866 |
| Slow response to stimuli | 45.71 | 42.86 | 9 | 1145 | 1979 | 110586166 |
| Faeces hard | 44.28 | 42.86 | 10 | 1144 | 4236 | 110583909 |
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002614 | Chelating Agents |
| MeSH PA | D007502 | Iron Chelating Agents |
| MeSH PA | D064449 | Sequestering Agents |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Hyperphosphatemia | contraindication | 20165001 | DOID:0050459 |
| Hypervitaminosis D | contraindication | 27712000 | DOID:9971 |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hypercalciuria | contraindication | 71938000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| 4020557 | VUID |
| N0000148263 | NUI |
| 4020557 | VANDF |
| CHEBI:50369 | CHEBI |
| CHEMBL3185022 | ChEMBL_ID |
| C030614 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB11255 | DRUGBANK_ID |
| S71T8B8Z6P | UNII |
| 59308 | RXNORM |
| 38299 | MMSL |
| 4442 | MMSL |
| 6684 | MMSL |
| d04142 | MMSL |
| 005140 | NDDF |
| C0163657 | UMLSCUI |
| 151932 | PUBCHEM_CID |
| C079689 | MESH_SUPPLEMENTAL_RECORD_UI |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vita-Rx Diabetic Vitamin | HUMAN PRESCRIPTION DRUG LABEL | 14 | 69677-050 | CAPSULE, GELATIN COATED | 0.47 mg | ORAL | unapproved drug other | 5 sections |